LOXL2 and diabetic kidney disease: This investigation employs an integrated experimental strategy to define the pathogenic contribution of endothelial LOX/LOXL2 in diabetic microvascular crosstalk and to substantiate Verbascoside as a mechanistically driven therapeutic candidate for DKD.